Press Releases Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
2.05 ^USD	-3.76%		+11.41%	+45.39%

Apr. 24	Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	CI
Apr. 17	Clarify Pharma to change name to File Forge Technology	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	Apr. 25	AQ
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	Apr. 24	GL
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	Apr. 17	GL
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements	Apr. 08	AQ
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 in Treatment Resistant Depression	Mar. 28	AQ
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	Mar. 28	GL
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	Mar. 28	AQ
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	Mar. 27	GL
Atai Life Sciences advances VLS-01 for treatment-resistant depression	Mar. 12	AQ
Atai Life Sciences N : Company Presentation March 2024	Mar. 04	PU
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	Mar. 04	GL
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	Mar. 04	AQ
Atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference	Feb. 28	GL
Atai Life Sciences Appoints Anne Johnson as Chief Financial Officer	Feb. 06	GL
Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics	Jan. 04	AQ
Atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics	Jan. 04	GL
Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01	Jan. 03	AQ
Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)	Jan. 02	GL
Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights	Nov. 14	GL
Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights	Nov. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Press Releases

Filters